Chronic Pain Clinical Trials Data Media 
Cannabis Law Report
DECEMBER 20, 2021
Data To Support Regulatory Filings in the United States. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., BERWYN, Pa.–(BUSINESS
Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 22, 2021
Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.
Cannabis Law Report
DECEMBER 8, 2021
Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.
Cannabis Law Report
NOVEMBER 10, 2021
The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain. Media: Laura Radocaj. In October 2021, Virpax announced that a $1.87 Christopher M. Betsy Brod.
Weedistry
JANUARY 28, 2019
The data also indicate that fentanyl and other fentanyl-related substances continue to be a major driver of this crisis,” Health Canadanotes. It’s when presented with personal stories like that of the Rhodes family and the stream of alarming data that the significance of Tetra Bio-Pharma’s (TBP) clinical trials is worth exploring.
Puff Puff Post
SEPTEMBER 16, 2019
Media are invited to attend an open house to learn more about the program and visit the recently expanded Santé Cannabis clinic and research centre in Montréal including a guided tour. RSVP: If you’d like to attend, please RSVP with Lilia Rassoul ( media@santecannabis.ca ). Time: 9:00AM to 5:00PM. ABOUT SANTÉ CANNABIS.
Expert insights. Personalized for you.
52 
Let's personalize your content